VEGFA and neoplasm: Cetuximab could bind to EGFR and play a role in blocking the binding sites between EGFR and endogenous ligands, thereby reducing abnormal intracellular signaling activation and transduction, inhibiting cell growth, inducing tumor cell apoptosis, and reducing the number of matrix metalloproteinases and VEGF[23].